Therapeutic alternatives for the treatment of residual hansenoma in patients with cure criteria of leprosy

Alternativas terapêuticas no tratamento de hansenomas residuais em paciente com critérios de cura de hanseníase

ABSTRACT

Hansenomas originate from the intense cutaneous infiltration by Mycobacterium leprae bacilli in Virchowian hansenic patients who tend to improve with treatment, however can develop keloid reactions. Alternative approaches are described for the treatment of disseminated receding hansenomas in the ears, face, upper limbs, and trunk in already treated virchowian patients. The exeresis of the lesion in the left ear was carried out and followed by injections of triamcinolone in the surgical scar, combined with simple injections in other lesions in exposed areas and an expectant approach in other areas. A good cosmetic result was observed in the excised lesion, in addition to a reduction in the lesions injected with corticosteroids. These procedures are easy to perform and cost effective, yielding good aesthetic outcomes.

Keywords: leprosy; leprosy, lepromatous; Mycobacterium leprae; therapeutic uses

RESUMO

Os hansenomas originam-se da infiltração cutânea acentuada por bacilos do Mycobacterium leprae em hansênicos virchowianos. Tendem a involuir com tratamento, mas podem desenvolver reações que-loidianas. Descrevem-se alternativas na abordagem de hansenomas em regressão disseminados em orelhas, face, membros superiores e tronco em paciente virchowiano já tratado. Realizou-se exérese da lesão em orelha esquerda seguida de infiltrações de triancinolona na cicatriz cirúrgica, apenas infiltrações nas outras lesões em áreas expostas e conduta expectante nas demais. Observaram-se bom resultado estético na lesão excisada e redução nas lesões infiltradas com corticoide. Os procedimentos são de fácil execução, baixo custo e boa resposta estética.

Palavras-chave: hanseníase; hanseníase virchowiana; Mycobacterium leprae; usos terapêuticos

Authors:
Patrick Alexander Wachholz
Paula Yoshiko Masuda
Christiane Salgado Sette

1 Geriatric physician, Bauru (SP), Brazil.
2 Dermatologist physician, Volunteer Preceptor, Instituto Lauro de Souza Lima, Bauru (SP), Brazil.
3 Dermatology Resident physician, Instituto Lauro de Souza Lima, Bauru (SP), Brazil.

Correspondence:
Paula Yoshiko Masuda
Rod. Comandante João Ribeiro de Barros, km 225/226
Cep: 17034-971 – Bauru - SP, Brazil
Email: paula.masuda@yahoo.com.br

Received on: 16/02/2015
Approved on: 19/08/2015

The present study was conducted at the Instituto Lauro de Souza Lima, Bauru (SP), Brazil.

Financial support: None

Conflict of interests: None
INTRODUCTION

The pathophysiology of the Hansen’s disease manifestations is related to the immune response of the host, to complications of peripheral neurologic involvement and to cellular/tissue damage secondary to the multiplication and dissemination of bacilli. In the anergic pole of the disease, the absence of cellular immunity against *Mycobacterium leprae* in patients with Virchowi-an hanseniasis (VH) triggers characteristic clinical manifestations due to the infiltration of the bacilli throughout the skin’s depth.

When the bacillary infiltration is intense, a polymorphism of lesions can be observed, including papules, tubercles, nodules, diffuse infiltration and ulcerations, in addition to cutaneous plaques termed hansenomas. The hansenomas usually only spare axial regions (vertebral spine, Michaelis’ polygon) and body areas with higher temperature, such as the groin, axillary and regions, and popliteal cavius.

With the establishment of multibacillary polychemotherapy (Mb-PCT), the hansenomas tend to regress spontaneously. In exceptional cases, however, they may persist (hansenomas in regression) or develop with fibroblast proliferation and keloidal reactions.

The correct diagnosis of lesions suggestive of hansenomas is crucial for the latter constitute a potential source of contagion in case there are viable bacilli. Furthermore, the presence of voluminous lesions or a great number of lesions significantly undermines the quality of life and contributes to the stigmatization of patients.

The present report describes and reviews different techniques and discusses evidences of potential therapeutic alternatives for hansenomas in regression associated with keloidal reaction in a patient with treated VH.

CASE REPORT

A 52 year-old male patient from the Brazilian Southeast Region seaside town of Itanhaém (SP) was diagnosed with VH at another dermatologic care service in the first half of 2009. He received Mb-PCT for 24 months due to high bacillary quantity and great number of hansenoma type cutaneous lesions. There was absence of record of dapsone based monotherapy, and the patient denied cutaneous trauma or acne. At the end of the Mb-PCT, few hansenomas had regressed. He was referred to a tertiary dermatologic service in July 2013 for evaluation of the possibility of drug resistance or disease activity.

On admission, the patient had a great number of erythematous nodular, hyperchromic and painless lesions, in the face, ears, chest, abdomen and upper limbs. The biopsy revealed hansenoma in regression, with histiocytes containing multifragmented bacilli, slightly colored/discolored, permeated by lymphocytes and plasmocytes, with dermal stromal proliferation of the hypertrophic scar/keloid type forming hyalinized collagen bands. The bacilloscopy came out positive, with a bacillary index of 2.34, a morphological index of 0, and a reagent PGL-1 test. The diagnosis was: treated VH with presence of hansenomas in regression associated with fibroblast proliferation of the keloidal type.

Figure 1: A - Multiple nodular, erythematous lesion with firm consistency, some hyperchromic, in the trunk and left upper limb, anterolateral view, before the interventions; B - Frontal view of the lesions on the trunk and upper limbs; C - Nodular lesions in the face and cervical region; D - Detail of the left auricular lesion, pedunculated, keloidal type, before the interventions.
Due to the unsightly nature of lesion in the left ear (Figure 1D), the great number of residual lesions in the trunk and exposed areas (Figures 1 A-B), and to the lack of evidence of the effectiveness of alternative therapies for such unusual lesions, three different types of interventions were proposed and consented by the patient.

The decision in favor of comparing the results in the same patient was aimed at not only avoiding lengthy procedures – which were unlikely to recover the aesthetics idealized by the patient – but also empirically assessing the superiority of the modalities from the patient’s and the team’s subjective opinion.

The surgical excision of the lesion in the left ear was carried out, followed by triamcinolone injections in the surgical scar. In the hansenomas located in exposed areas (face and upper limbs) only injections of corticosteroids were performed. An expectant approach was adopted in the other lesions.

The lesion in the earlobe was pedunculated due to local skin laxity. The technique included the marking of the lesion, anesthesia with 2% lidocaine, fusiform incision, detachment in layers, preparation of the flap by sliding the margins, and simple suture with nylon 6.0 monofilament. The stitches were removed on the 9th postoperative day, with two injections having been carried out in 30-day intervals, with 20mg/ml triamcinolone hexacetonide at a dose of 0.2 ml per injection.

In the lesions located in the face and upper limbs, two sessions of intraleisional corticosteroid injections with the same substance were applied in each lesion, at a dose of 0.8 ml per session, observing the same time interval between sessions. The lesions located in the trunk were only monitored during the follow-up period.

Six months after it was possible to observe an excellent aesthetic result in the lesion located in the ear, without recurrence (Figure 3 A-B). The lesions that received injections had

---

**Figure 2:**
A – Hematoxylin-eosin (HE) staining, 100x: skin (left ear nodule) with Virchowian granulomas in regression, predominantly consisting of multivacuolated macrophages and lymphocytes, surrounded by dense connective tissue bands;
B – HE staining, 400x: details of the granulomas, surrounded by bands of connective tissue, composed of fibroblasts and collagen fibers;
C – Fite-Faraco staining, 100x: presence of multivacuolated discolored bacilli in granulomas in regression;
D – Fite-Faraco staining, 400x: details of multivacuolated bacilli and discolored present in the granuloma of Figure 2C

---

**Figure 3:**
A – Left hemiface and left ear lobe after resection of the pedunculated lesion, lobe reconstruction, and corticosteroid injection in the surgical scar and in lesions in the face and cervical region;
B – Details of the volume reduction of hansenomas in regression associated with keloidal reaction after two corticosteroid injections in the cervical region and face
mild to moderate reduction (Figure 4 A–B). The lesions that were under expectant approach remained unchanged. The patient’s and team’s perception of improvement was considered very good.

**DISCUSSION**

Despite having considered the possibility of histoid leprosy, this variety manifests with intensely bacillary lesions with the predominance of typical bacilli, potentially resistant to therapy. The nodules’ appearance is different, with well delimited, skin-color bright lesions, usually firm and translucent, with histology displaying numerous fusiform histiocytes and polygonal cells arranged in a crossed or intertwined characteristic spiral.

In the face of a hansenoma in regression with keloidal type reaction diagnosis, it is important to consider potential alternative therapies aimed at easing the disease’s stigma. The available evidence on the management of hypertrophic and keloid scars (not specifically related to leprosy) has been revised in recent years. Treatment strategies are largely determined by the lesion’s classification, and include silicone-based products, intralesional corticosteroids, 5-fluorouracil and intralesional bleomycin, radiotherapy, cryotherapy in addition to emerging treatment with mitomycin-C, imiquimod and onion extracts and heparin, as well as interventions and surgical laser. The first publications featuring topical mitomycin-C are also contradictory, indicating a possible advantage in the reduction of recurrence after surgical removal of the lesions, nevertheless with increased risk of ulceration.

**CONCLUSIONS**

The results observed in the development of the present case demonstrated that the procedures adopted, in addition to being cost effective, easy to implement and with good aesthetics and functional response, provided substantial improvements to the patient’s perception of quality life. The association of surgery and intralesional corticosteroid was the most effective, however it would not be feasible to apply it in all corporeal lesions.
REFERENCES

1. Schettini APM, Eiras J da C, Cunha M da GS, Tubilla LHM, Sardinha JCG. Hanseníase histióide de localização restrita. An Bras Dermatol. 2008;83(5):470-2.

2. Opromolla DVA. Manifestações clinicas e reações. Noções de hansenologia. Bauru: Centro de Estudos Dr. Reynaldo Quagliato; 2000. p. 51-8.

3. Batra N, Hatwal D, Dandona S. Histiod Leprosy - How Is It Different From Lepromatous Leprosy? A Case Report. J Med Sci Clin Res. 2014;2(3):555-8.

4. Dyer RF, Enna CD. Ultrastructure of keloid: an unusual incident involving lepromatous leprosy. Int J Dermatol. 1975;14(10):743-54.

5. Sehgal VN, Aggarwal A, Srivastava G, Sharma N, Sharma S. Evolution of histoid leprosy (de novo) in lepromatous (multibacillary) leprosy. Int J Dermatol. 2005;44(7):576-8.

6. Ledon JA, Savas J, Franca K, Chacon A, Nouri K. Intralional treatment for keloids and hypertrophic scars: a review. Dermatol Surg. 2013;39(12):1745-57.

7. Wolfram D, Tzankov A, Püzül P, Piza-Katzer H. Hypertrophic scars and keloids—a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg. 2009;35(2):171-81.

8. Gold MH, McGuire M, Mustoe TA, Pusic A, Sachdev M, Waibel J, et al. Updated international clinical recommendations on scar management: part 2—algorithms for scar prevention and treatment. Dermatol Surg. 2014;40(8):825-31.

9. Meaume S, Le Pillouer-Prost A, Richert B, Roseeuw D, Vadoud J. Management of scars: updated practical guidelines and use of silicones. Eur J Dermatol. 2014;24(4):435-43.

10. Rabello FB, Souza CD, Farina Júnior JA. Update on hypertrophic scar treatment. Clinics (Sao Paulo). 2014;69(8):565-73.